StemCell Therapy

May 30, 2017 05:15 ET | Source: Research and Markets

Dublin, May 30, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Biosimilars Market Access in Psoriatic Arthritis" report to their offering.

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market. These market leaders, however, face patent expirations and consequent biosimilar launches.

Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors.

The rate of this erosion is likely to be gradual initially, as both physicians and payers are not likely to advocate patient switching.

Key Topics Covered:

1. Executive Summary

2. Five Major EU Markets

3. Methodology

For more information about this report visit http://www.researchandmarkets.com/research/bczl5n/biosimilars

Related Articles

Research and Markets Logo

LOGO URL | Copy the link below

Formats available:

See the article here:
Global Psoriatic Arthritis Biosimilars Market Access Report 2017 - GlobeNewswire (press release)

This entry was posted on May 30, 2017 at 11:41 am and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |